### Hot Topic Discussion


# The rise of RNA Nanotherapeutics: Current Trends & Future Challenges

Drs. Coralie Backlund (Irvine Lab) and Ahmet Bekdemir (Bhatia Lab)

May 18, 2020





## What are RNA therapeutics?




Adapted from: Heart 103, 812-817 (2017)

# RNA therapeutics: a brief history





## Cancer RNA therapeutics are on the rise




## Current Technologies used for RNA delivery

Delivery vehicle	Type of RNA in clinical trials	Advantages	Disadvantages
Naked RNA	siRNA, ASO, mRNA	No additional materials or synthesis required	Prone to degradation Immunogenic Difficulty entering cell Poor circulation half-life
Nanoparticle	-	Increased half life Protection from nucleases Aids in endocytosis and endosomal escape	Elevated risk of toxicity with introducing excipient materials
Conjugate	siRNA, ASO	Defined chemical structure Ability to target specific receptors Limited toxicity due to lack of excipient materials	High doses required Dependent on chemical modifications for RNA stability


#### Inorganic




Organic




## Current Technologies used for RNA delivery



### Routes of administration for RNA delivery




### The Challenges of RNA Delivery




9

### Approaches to address challenges in RNA Delivery



What needs to happen for RNA delivery to make a difference in oncology?







Patient stratification

